2.50
Hdl Handle:
http://hdl.handle.net/10541/107639
Title:
Phase I clinical trial of methylene dimethane sulfonate.
Authors:
Smith, David B; Fox, Brian W; Thatcher, Nick; Steward, William P; Scarffe, J Howard; Wagstaff, John; Vezin, R; Crowther, Derek
Abstract:
Methylene dimethane sulfonate is the first member of the homologous series of straight-chain diol sulfonates. It was selected for phase I testing because of high activity in the rat Yoshida sarcoma system and a possible novel site of alkylation due to its small molecular size. Methylene dimethane sulfonate was administered as a rapid iv bolus infusion to 39 patients at doses ranging from 14 to 225 mg/m2. Nausea and vomiting were not severe but total alopecia occurred in the majority of patients at doses greater than 100 mg/m2. The dose-limiting toxic effect was thrombocytopenia, which was cumulative with lower, more prolonged nadirs following successive courses. The median time to platelet count nadir was 21 days, with recovery by 35 days. A minor response was seen in one patient with an adenocarcinoma of the lung. The recommended dose for phase II studies is 125 mg/m2 for patients who have received prior chemotherapy and 150 mg/m2 for those who have not, in an every 35-day schedule.
Citation:
Phase I clinical trial of methylene dimethane sulfonate. 1987 Sep;71(9):817-20 Cancer Treat Rep
Journal:
Cancer Treatment Reports
Issue Date:
Sep-1987
URI:
http://hdl.handle.net/10541/107639
PubMed ID:
3621213
Type:
Article
Language:
en
ISSN:
0361-5960
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorSmith, David Ben
dc.contributor.authorFox, Brian Wen
dc.contributor.authorThatcher, Nicken
dc.contributor.authorSteward, William Pen
dc.contributor.authorScarffe, J Howarden
dc.contributor.authorWagstaff, Johnen
dc.contributor.authorVezin, Ren
dc.contributor.authorCrowther, Dereken
dc.date.accessioned2010-07-14T14:58:54Z-
dc.date.available2010-07-14T14:58:54Z-
dc.date.issued1987-09-
dc.identifier.citationPhase I clinical trial of methylene dimethane sulfonate. 1987 Sep;71(9):817-20 Cancer Treat Repen
dc.identifier.issn0361-5960-
dc.identifier.pmid3621213-
dc.identifier.urihttp://hdl.handle.net/10541/107639-
dc.description.abstractMethylene dimethane sulfonate is the first member of the homologous series of straight-chain diol sulfonates. It was selected for phase I testing because of high activity in the rat Yoshida sarcoma system and a possible novel site of alkylation due to its small molecular size. Methylene dimethane sulfonate was administered as a rapid iv bolus infusion to 39 patients at doses ranging from 14 to 225 mg/m2. Nausea and vomiting were not severe but total alopecia occurred in the majority of patients at doses greater than 100 mg/m2. The dose-limiting toxic effect was thrombocytopenia, which was cumulative with lower, more prolonged nadirs following successive courses. The median time to platelet count nadir was 21 days, with recovery by 35 days. A minor response was seen in one patient with an adenocarcinoma of the lung. The recommended dose for phase II studies is 125 mg/m2 for patients who have received prior chemotherapy and 150 mg/m2 for those who have not, in an every 35-day schedule.en
dc.language.isoenen
dc.subjectMethylene Dimethane Sulfonateen
dc.subjectCanceren
dc.titlePhase I clinical trial of methylene dimethane sulfonate.en
dc.typeArticleen
dc.identifier.journalCancer Treatment Reportsen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.